Inactive Instrument

Press Releases Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
05-28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	06-12	AQ
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	06-11	AQ
European Biosimilar Regulatory Update	06-10	AQ
Corporate Presentation: June 2024	06-05	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	05-29	AQ
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	05-28	AQ
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	05-15	AQ
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	05-13	AQ
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	05-09	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	05-02	AQ
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	04-29	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	04-16	AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	04-15	AQ
Corporate Presentation: March 2024	03-28	PU
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-25	AQ
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-22	AQ
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	03-18	AQ
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split	03-13	AQ
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	03-12	AQ
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	02-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncobiologics Inc Nasdaq

Equities

US68235M2044

Press Releases

Filters